Navigation Links
Cardiac Science Announces Inclusion in Russell 3000 Index
Date:6/30/2008

BOTHELL, Wash., June 30 /PRNewswire-FirstCall/ -- Cardiac Science Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, announced today that it has been selected to join the Russell 3000(R) Index. The Company's addition to the Russell 3000 Index was made effective following the market close on Friday, June 27. Selection to the Russell 3000 index means Cardiac Science is automatically included in the Russell 2000(R) Index, which measures the performance of approximately 2,000 small-cap U.S. securities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

"We believe our inclusion in the Russell indexes will provide our company with greater visibility to a broader range of potential investors," said John Hinson, president and chief executive officer of Cardiac Science.

The Russell 3000 Index measures the performance of the largest 3,000 U.S. companies, and is constructed to provide a comprehensive, unbiased and stable barometer of the broad market. The Index is reconstituted annually. The Russell 2000 Index is a subset of the Russell 3000 Index.

About Cardiac Science

Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

CSCX-G

Company Contact: Investor Contact: Media Contact:

Mike Matysik Jenifer Kirtland or Christopher Gale

Cardiac Science Donald Takaya EVC Group, Inc.

Corporation EVC Group, Inc. (201) 646-5431

Sr. Vice President (415) 896-6820 (203) 570-4681

and CFO cgale@evcgroup.com

(425) 402-2009


'/>"/>
SOURCE Cardiac Science Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CardiacAssist, Inc. Surpasses 1300 TandemHeart System Procedures
2. Cardiac Science Launches Anywhere Data Management for HIS and EMR Systems
3. Braemar Introduces the ER920W Wireless Cardiac Arrhythmia Monitor
4. Cardiac Science to Present at Needham Biotechnology & Medical Technology Conference
5. Perceptive Informatics Enhances Medical Imaging Capabilities for Assessment of Cardiac Function
6. Increased Drug Related Cardiac Toxicity Leads Gwathmey Preclinical Testing Services to Create Novel Cardionomics(TM) Services for Preclinical Cardiac Safety Screening of Drug Candidates
7. CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair
8. CryoLife Conducts Surgeons Cardiac Allograft Symposium
9. Cardiac Science Schedules First Quarter Earnings Release and Announces Conference Call
10. The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium
11. eResearchTechnology, Inc. and nSpire Health, Inc. Form Alliance to Deliver Integrated Cardiac Safety and Pulmonary Clinical Trial Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):